Results 201 to 210 of about 525,575 (332)

Relative efficacy of GLP‐1 and GLP‐1/GIP receptor agonists in the prevention of alcohol‐use disorders using a target trial emulation approach

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 137-150, January 2026.
Abstract Aims There is growing evidence that the GLP‐1 system is implicated in alcohol and other substance use disorders, and that GLP‐1‐based therapies may have therapeutic relevance in alcohol use disorder (AUD). We aimed to determine the impact of GLP‐1 based therapies on incident AUDs in a real‐world setting in patients with T2D.
Alex E. Henney   +8 more
wiley   +1 more source

The estrous cycle moderates the food and body weight suppressive effects of glucagon‐like peptide‐1 receptor agonism

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 221-230, January 2026.
Abstract Aims Emerging data suggest more young women than men are prescribed weight loss pharmacotherapies targeting the glucagon‐like peptide‐1 receptor (GLP‐1R). However, preclinical literature has largely used male animals to characterize the neural mechanisms underlying the weight loss abilities of GLP‐1R agonists (GLP‐1RAs), highlighting a need ...
Sarah V. Applebey   +3 more
wiley   +1 more source

Nucleus Accumbens Acetylcholine Receptors Modulate Dopamine and Motivation

open access: yesNeuropsychopharmacology, 2016
Anne L. Collins   +4 more
semanticscholar   +1 more source

Psychiatric effects of GLP‐1 receptor agonists: A systematic review of emerging evidence

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 50-59, January 2026.
Abstract This systematic review examines the current literature on glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs)‐associated psychiatric manifestations, including depression, suicidality, eating disorders, substance use disorders (SUD) and schizophrenia spectrum disorders.
Brianna Sa   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy